The role of the nicotinic acetylcholine receptors in sleep-related epilepsy.

Epilepsy, Neurophysiology and Neurogenetics Unit, Department of Child Neurology and Psychiatry, IRCCS Stella Maris Foundation, Pisa, Italy.
Biochemical Pharmacology (Impact Factor: 4.65). 11/2007; 74(8):1308-14. DOI: 10.1016/j.bcp.2007.06.030
Source: PubMed

ABSTRACT The role of neuronal acetylcholine receptors (nAChRs) in epilepsy has been clearly established by the finding of mutations in a subset of genes coding for subunits of the nAChRs in a form of sleep-related epilepsy with familial occurrence in about 30% of probands and dominant inheritance, named autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE). Sporadic and familial forms have similar clinical and EEG features. Seizures begin in middle childhood as clusters of sleep-related attacks with prominent motor activity, and sustained dystonic posturing. In addition to nocturnal seizures, psychosis or schizophrenia, behavioral disorders, memory deficits and mental retardation were described in some individuals. Although over hundred families are on record, only a minority of them have been linked to mutations in the genes coding for the alpha4, alpha2 and beta2 (CHRNA4, CHRNA2, and CHRNB2) subunits of the nAChRs, indicating that ADNFLE is genetically heterogeneous despite a relatively homogeneous clinical picture. Functional characterization of some mutations suggests that gain of the receptor function might be the basis for epileptogenesis. In vitro and in vivo studies have shown high density of nAChRs in the thalamus, over activated brainstem ascending cholinergic pathway and enhanced GABAergic function, reinforcing the hypothesis that cortico-subcortical networks, regulating arousal from sleep, play a central role in seizure precipitation in ADNFLE.

  • [Show abstract] [Hide abstract]
    ABSTRACT: So far, only two mutations in the CHRNA4 gene (in three studies) and one mutation in the CHRNB2 gene had been identified in the patients with sporadic nocturnal frontal lobe epilepsy (NFLE). The absence of mutations in the candidate genes in the majority of sporadic NFLE patients suggest that they are rare loci for the disease, but the necessity of performing genetic testing for sporadic cases should not be neglected. We designed mutation screening of exon 5 of CHRNA4, exon 5 of CHRNB2, and exon 6 of CHRNA2 in a group of 56 Chinese sporadic NFLE cases. A de novo missense mutation in the transmembrane domain M2 segment of the α4 subunit of the neuronal nicotinic acetylcholine receptor, c.823A > T, was found in a 15 year-old right-handed male, but was not observed in his parents and 400 control chromosomes. The mutation decreased the surrounding hydrophobicity and slightly altered secondary structure of the protein. No mutations were found in CHRNB2 and CHRNA2.
    Epilepsy Research 09/2014; 108(10). DOI:10.1016/j.eplepsyres.2014.08.024 · 2.19 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: The DEPDC5 (DEP domain-containing protein 5) gene, encoding a repressor of the mTORC1 signaling pathway, has recently emerged as a major gene mutated in familial focal epilepsies. We aimed to further extend the role of DEPDC5 to focal cortical dysplasias (FCDs).Methods: Seven patients from four families with DEPDC5 mutations, and focal epilepsy associated with FCD were recruited and investigated at the clinical, neuroimaging and histopathological levels. The DEPDC5 gene was sequenced from genomic blood and brain DNA.Results: All patients had drug-resistant focal epilepsy, five of them underwent surgery, and one a brain biopsy. Electroclinical phenotypes were compatible with FCD II, although MRI was typical in only four cases. Histopathology confirmed FCD IIa in two patients (including one MRI-negative case) and showed FCD I in two other patients, and remained inconclusive in the last two. Three patients were seizure-free post-surgically and one had a worthwhile improvement. Sequencing of blood DNA revealed truncating DEPDC5 mutations in all four families; one mutation was found to be mosaic in an asymptomatic father. A brain somatic DEPDC5 mutation was identified in one patient in addition to the germline mutation.Interpretation: Germline, germline mosaic and brain somatic DEPDC5 mutations may cause epilepsy associated with FCD, reinforcing the link between mTORC1 pathway and FCDs. Similarly to other mTORopathies, a “two-hit” mutational model could be responsible for cortical lesions. Our study also indicates that epilepsy surgery is a valuable alternative in the treatment of drug-resistant DEPDC5-positive focal epilepsies, even if the MRI is unremarkable. This article is protected by copyright. All rights reserved.
    Annals of Neurology 01/2015; DOI:10.1002/ana.24368 · 11.91 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Rare multiplex families with autosomal dominant focal epilepsies have been described with specific age-related and electroclinical syndromes: autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), familial temporal lobe epilepsy (FTLE), and familial focal epilepsy with variable foci (FFEVF). Molecular genetic advances in inherited focal epilepsies have pinpointed their genetic heterogeneity and the fact that they are mediated by different biological pathways: ion channel subunit genes have been linked to ADNFLE (CHRNA4, CHRNA2, CHRNB2, and KCNT1, encoding, respectively, the α4, α2, and β2 subunits of the neuronal nicotinic acetylcholine receptor, and a potassium channel subunit); neuronal secreted protein (LGI1-encoding epitempin) has been linked to autosomal dominant epilepsy with auditory features; and mTORC1-repressor DEPDC5 (DEP domain-containing protein 5) gene has recently been reported in a broad spectrum of inherited focal epilepsies (ADNFLE, FTLE, FFEVF). This chapter focuses on DEPDC5, a newly identified gene.
    Progress in brain research 01/2014; 213C:123-139. DOI:10.1016/B978-0-444-63326-2.00007-7 · 5.10 Impact Factor